BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shaw PJ, Beggs KM, Sparkenbaugh EM, Dugan CM, Ganey PE, Roth RA. Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. Toxicol Sci 2009;111:288-301. [PMID: 19638433 DOI: 10.1093/toxsci/kfp163] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Goldring C, Weaver R, Kramer B, Klingmueller U, Oppelt A, Van der Water B, Commandeur J, Guillouzo A, Naisbitt D, French N, Kitteringham N, Pridgeon C, Knolle P, Sidaway J, Sison-young R, Kamalian L, Mercer A, Faulkner L, Pieters R, Ingelman-sundberg M, Kevin Park B. Drug-Induced Liver Injury: Mechanism-Informed Prediction in Drug Development. Comprehensive Medicinal Chemistry III. Elsevier; 2017. pp. 217-38. [DOI: 10.1016/b978-0-12-409547-2.12384-4] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
2 Yang H, Park T, Park D, Kang M. Trovafloxacin drives inflammation-associated drug-induced adverse hepatic reaction through changing macrophage polarization. Toxicology in Vitro 2022. [DOI: 10.1016/j.tiv.2022.105374] [Reference Citation Analysis]
3 Lu J, Einhorn S, Venkatarangan L, Miller M, Mann DA, Watkins PB, LeCluyse E. Morphological and Functional Characterization and Assessment of iPSC-Derived Hepatocytes for In Vitro Toxicity Testing. Toxicol Sci 2015;147:39-54. [PMID: 26092927 DOI: 10.1093/toxsci/kfv117] [Cited by in Crossref: 74] [Cited by in F6Publishing: 58] [Article Influence: 10.6] [Reference Citation Analysis]
4 Corsini A, Ganey P, Ju C, Kaplowitz N, Pessayre D, Roth R, Watkins PB, Albassam M, Liu B, Stancic S. Current challenges and controversies in drug-induced liver injury. Drug Saf. 2012;35:1099-1117. [PMID: 23137150 DOI: 10.2165/11632970-000000000-00000] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Giustarini G, Kruijssen L, van Roest M, Bleumink R, Weaver RJ, Bol-schoenmakers M, Smit J, Pieters R. Tissue influx of neutrophils and monocytes is delayed during development of trovafloxacin-induced tumor necrosis factor-dependent liver injury in mice: Delayed influx of innate immune cells in drug-induced liver injury. J Appl Toxicol 2018;38:753-65. [DOI: 10.1002/jat.3585] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
6 Roth RA, Ganey PE. Animal models of idiosyncratic drug-induced liver injury—Current status. Critical Reviews in Toxicology 2011;41:723-39. [DOI: 10.3109/10408444.2011.575765] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
7 Liguori MJ, Ditewig AC, Maddox JF, Luyendyk JP, Lehman-McKeeman LD, Nelson DM, Bhaskaran VM, Waring JF, Ganey PE, Roth RA, Blomme EA. Comparison of TNFα to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: Trovafloxacin as an example. Int J Mol Sci 2010;11:4697-714. [PMID: 21151465 DOI: 10.3390/ijms11114697] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
8 Roth RA, Maiuri AR, Ganey PE. Idiosyncratic Drug-Induced Liver Injury: Is Drug-Cytokine Interaction the Linchpin? J Pharmacol Exp Ther 2017;360:461-70. [PMID: 28104833 DOI: 10.1124/jpet.116.237578] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
9 Weaver RJ, Blomme EA, Chadwick AE, Copple IM, Gerets HHJ, Goldring CE, Guillouzo A, Hewitt PG, Ingelman-sundberg M, Jensen KG, Juhila S, Klingmüller U, Labbe G, Liguori MJ, Lovatt CA, Morgan P, Naisbitt DJ, Pieters RHH, Snoeys J, van de Water B, Williams DP, Park BK. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nat Rev Drug Discov 2020;19:131-48. [DOI: 10.1038/s41573-019-0048-x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 16.0] [Reference Citation Analysis]
10 Hsiao CJ, Younis H, Boelsterli UA. Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction. Chemico-Biological Interactions 2010;188:204-13. [DOI: 10.1016/j.cbi.2010.07.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
11 Bonzo JA, Rose K, Freeman K, Deibert E, Amaral KB, Ferguson SS, Andersen ME, Witek RP, Lecluyse EL. Differential Effects of Trovafloxacin on TNF-α and IL-6 Profiles in a Rat Hepatocyte–Kupffer Cell Coculture System. Applied In Vitro Toxicology 2015;1:45-54. [DOI: 10.1089/aivt.2014.0004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
12 Beggs KM, Maiuri AR, Fullerton AM, Poulsen KL, Breier AB, Ganey PE, Roth RA. Trovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia telangiectasia and Rad3-related. Toxicology 2015;331:35-46. [PMID: 25748550 DOI: 10.1016/j.tox.2015.03.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
13 Ahn JH, Jegal H, Choi MS, Kim S, Park SM, Ahn J, Han HY, Cho HS, Yoon S, Oh JH. TNFα enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Toxicol Lett 2021;342:73-84. [PMID: 33609687 DOI: 10.1016/j.toxlet.2021.02.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Poulsen KL, Olivero-Verbel J, Beggs KM, Ganey PE, Roth RA. Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response. J Pharmacol Exp Ther 2014;350:164-70. [PMID: 24817034 DOI: 10.1124/jpet.114.214189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
15 Roth RA, Ganey PE. Role of Inflammation in Drug-Induced Liver Injury. Drug-Induced Liver Disease. Elsevier; 2013. pp. 157-73. [DOI: 10.1016/b978-0-12-387817-5.00010-8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
16 Ramaiahgari SC, Waidyanatha S, Dixon D, DeVito MJ, Paules RS, Ferguson SS. From the Cover: Three-Dimensional (3D) HepaRG Spheroid Model With Physiologically Relevant Xenobiotic Metabolism Competence and Hepatocyte Functionality for Liver Toxicity Screening. Toxicol Sci 2017;159:124-36. [PMID: 28633424 DOI: 10.1093/toxsci/kfx122] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
17 Beggs KM, Fullerton AM, Miyakawa K, Ganey PE, Roth RA. Molecular mechanisms of hepatocellular apoptosis induced by trovafloxacin-tumor necrosis factor-alpha interaction. Toxicol Sci 2014;137:91-101. [PMID: 24097668 DOI: 10.1093/toxsci/kft226] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
18 Poulsen KL, Albee RP, Ganey PE, Roth RA. Trovafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release from RAW 264.7 cells requires extracellular signal-regulated kinase and c-Jun N-Terminal Kinase. J Pharmacol Exp Ther 2014;349:185-91. [PMID: 24525298 DOI: 10.1124/jpet.113.211276] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
19 Wink S, Hiemstra SW, Huppelschoten S, Klip JE, van de Water B. Dynamic imaging of adaptive stress response pathway activation for prediction of drug induced liver injury. Arch Toxicol 2018;92:1797-814. [PMID: 29502165 DOI: 10.1007/s00204-018-2178-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
20 Lu J, Miyakawa K, Roth RA, Ganey PE. Tumor necrosis factor-alpha potentiates the cytotoxicity of amiodarone in Hepa1c1c7 cells: roles of caspase activation and oxidative stress. Toxicol Sci 2013;131:164-78. [PMID: 23042730 DOI: 10.1093/toxsci/kfs289] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
21 Gao Y, Xu G, Ma L, Shi W, Wang Z, Zhan X, Qin N, He T, Guo Y, Niu M, Wang J, Bai Z, Xiao X. Icariside I specifically facilitates ATP or nigericin-induced NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Cell Commun Signal 2021;19:13. [PMID: 33573688 DOI: 10.1186/s12964-020-00647-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Corsini A, Ganey P, Ju C, Kaplowitz N, Pessayre D, Roth R, Watkins PB, Albassam M, Liu B, Stancic S, Suter L, Bortolini M. Current Challenges and Controversies in Drug-Induced Liver Injury. Drug Saf 2012;35:1099-117. [DOI: 10.1007/bf03261997] [Cited by in Crossref: 44] [Cited by in F6Publishing: 14] [Article Influence: 4.4] [Reference Citation Analysis]
23 Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, Aleo MD. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 2011;24:1345-410. [PMID: 21702456 DOI: 10.1021/tx200168d] [Cited by in Crossref: 449] [Cited by in F6Publishing: 388] [Article Influence: 40.8] [Reference Citation Analysis]
24 Shaw PJ, Ganey PE, Roth RA. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci 2010;118:7-18. [PMID: 20538741 DOI: 10.1093/toxsci/kfq168] [Cited by in Crossref: 84] [Cited by in F6Publishing: 67] [Article Influence: 7.0] [Reference Citation Analysis]
25 Giustarini G, Vrisekoop N, Kruijssen L, Wagenaar L, van Staveren S, van Roest M, Bleumink R, Bol-Schoenmakers M, Weaver RJ, Koenderman L, Smit J, Pieters R. Trovafloxacin-Induced Liver Injury: Lack in Regulation of Inflammation by Inhibition of Nucleotide Release and Neutrophil Movement. Toxicol Sci 2019;167:385-96. [PMID: 30247740 DOI: 10.1093/toxsci/kfy244] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
26 Mitsugi R, Itoh T, Fujiwara R. MicroRNA-877-5p is involved in the trovafloxacin-induced liver injury. Toxicol Lett 2016;263:34-43. [PMID: 27713024 DOI: 10.1016/j.toxlet.2016.10.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
27 Kwast L, Fiechter D, Kruijssen L, Bleumink R, Ludwig I, Bol-Schoenmakers M, Smit J, Pieters R. Oral exposure to immunostimulating drugs results in early changes in innate immune parameters in the spleen. J Immunotoxicol 2016;13:535-47. [PMID: 27043250 DOI: 10.3109/1547691X.2016.1139643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
28 Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother. 2011;66:1431-1446. [PMID: 21586591 DOI: 10.1093/jac/dkr159] [Cited by in Crossref: 93] [Cited by in F6Publishing: 76] [Article Influence: 8.5] [Reference Citation Analysis]